anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides an application of an ARHGEF19 antisense nucleotide sequence in preparing a medicament for inhibiting the growth of tumor cells. The targeting sequence of the ARHGEF19 antisense nucleotide sequence is a sequence shown as SEQ ID NO.1 or SEQ ID NO.2 positioned on ARHGEF 19. The positive and negative sequences of the ARHGEF19 antisense nucleotide sequence are respectively shown as SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 or SEQ ID NO. 6. Also provided is an expression vector of the ARHGEF19 antisense nucleotide sequence. The invention provides a targeted treatment strategy aiming at the condition of poor treatment effect of the existing small cell lung cancer, and reduces the expression of ARHGEF19 through the antisense nucleotide sequence of ARHGEF19, thereby inhibiting the growth of small cell lung cancer cells.
This randomized controlled study will involve at least 50 evaluable subjects divided evenly among 5 study sites in Taiwan. Each study site will enroll 12 subjects at least. The ration of evaluable test subjects to control subjects will be 2 to 1. Subjects who have normal ocular health and conform to a set of standard criteria will wear one of the study lenses on two eyes and follow up for 3 months (90 days). Lenses will be assigned to subject according to a predetermined randomized order. It is necessary to remove contact lenses every day and replace after 30 days. Any unscheduled visit will be allowed when there is a medication necessary. The data for slit lamp findings, symptoms/problems/complaints, keratometry (K) reading, refractive changes (absolute value), visual acuity data, average wear time (AWT), discontinuations, and lens replacement will be collected to claim that the VISCO Soft Contact Lens is as safe and effective as BIOFINITY (comfilcon A) Soft Contact Lens (CooperVision).
Participants were randomized to receive an arm. In this arm, participants received leg cycling exercise program in the form of high-intensity interval training for 28 min/day, 3 days/week for 8 weeks. Exercise training was performed at Burapha University.
A system for processing, communication and viewing of medical imaging study data is configured to process and communicate medical imaging study data for communication between a local system and a client terminal. The systems preferably include a local system, one or more client terminals and an intermediate remote server. The local system may be located within a Virtual Private Network (VPN) and includes a local or site server, a Picture Archiving and Communication System (PACS) and a Radiology Information System (RIS). The local or site server communicates between the PACS and the RIS, and the intermediate remote server that may be outside of the VPN. The local or site server may be configured to perform a lossless image processing method to process, compress and encrypt and communicate medical imaging study data. An interface and associated methods of viewing medical imaging study data are also disclosed.
Participants with HER2-positive MBC will receive docetaxel 60 mg/m\^2 IV infusion and T-DM1 2.4 mg/kg IV infusion on Day 1 of each 3-week cycle for a minimum of 6 cycles. After 6 cycles, docetaxel 60 mg/m\^2 will be stopped and T-DM1 2.4 mg/kg will be continued until confirmed evidence of disease progression, unacceptable toxicity, or withdrawal of participant consent.
Asthma is a very common disorder which causes a great deal of distress for patients, and occasionally results in premature death. Approximately 10% of people with asthma have severe disease which is not helped by current treatments; The Investigators need to find new treatments for these patients urgently. Patients with asthma are not all the same, but have distinct features which characterise their asthma.The Investigators therefore hypothesise that asthma is not a single disease, but a syndrome resulting from several distinct underlying disease processes known as endotypes. There are approximately 30,000 genes in humans, and each gene is responsible for the production of a particular protein. Using a technique called "whole genome expression profiling" The Investigators have undertaken a small study looking at the activity of all 30,000 genes in the airway tissue of people with asthma. This work has identified 3 mutually exclusive distinct molecular patterns (endotypes) of severe asthma and has identified other potentially important molecular targets (manuscripts in preparation).

In particular, the Investigators have found that 25-50% of patients have asthma associated with the activity of proteins called Th2 cytokines (Th2-high asthma). New treatments are in development that target this pathway. However, the Investigators do not know what is driving severe asthma in patients who do not express these Th2 cytokines. The aim of this study is to investigate in more detail the molecular mechanisms driving severe asthma in patients who do not express Th2 cytokines (Th2-low asthma), so that the Investigators can identify new targets for treatment in this group. To do this the Investigators will collect airway tissue via a telescope (bronchoscope), and analyse gene and protein expression in the tissue. The Investigators will then compare the molecular activity between patients with Th2-high and Th2-low asthma, and healthy control subjects (data obtained from a parallel study).
Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel open probability (or gating) of CFTR protein located at the cell surface. The overall level of ivacaftor-mediated CFTR chloride transport is dependent on the amount of CFTR protein at the cell surface and how responsive a particular mutant CFTR protein is to ivacaftor potentiation. 

CFTR Chloride Transport Assay in Fisher Rat Thyroid (FRT) cells expressing mutant CFTR

The chloride transport response of mutant CFTR protein to ivacaftor was determined in Ussing chamber electrophysiology studies using a panel of FRT cell lines transfected with individual CFTR mutations. Ivacaftor increased chloride transport in FRT cells expressing CFTR mutations that result in CFTR protein being delivered to the cell surface. 

The in vitro CFTR chloride transport response threshold was designated as a net increase of at least 10% of normal over baseline because it is predictive or reasonably expected to predict clinical benefit. For individual mutations, the magnitude of the net change over baseline in CFTR-mediated chloride transport in vitro is not correlated with the magnitude of clinical response. A patient must have at least one CFTR mutation responsive to ivacaftor to be indicated.

Note that splice site mutations cannot be studied in the FRT assay. Evidence of clinical efficacy exists for non-canonical splice mutations 2789+5G→A, 3272-26A→G, 3849+10kbC→T, 711+3A→G and E831X and these are listed in Table 3 below [see also Clinical Studies (14.4)]. The G970R mutation causes a splicing defect resulting in little-to-no CFTR protein at the cell surface that can be potentiated by ivacaftor [see Clinical Studies (14.2)].

Ivacaftor also increased chloride transport in cultured human bronchial epithelial (HBE) cells derived from CF patients who carried F508del on one CFTR allele and either G551D or R117H-5T on the second CFTR allele.

Table 3 lists mutations that are responsive to ivacaftor based on 1) a positive clinical response and/or 2) in vitro data in FRT cells indicating that ivacaftor increases chloride transport to at least 10% over baseline (% of normal).
OD-C includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded.
No studies have been performed to test the potential of atezolizumab for carcinogenicity or genotoxicity.

Animal fertility studies have not been conducted with atezolizumab; however, an assessment of the male and female reproductive organs was included in a 26-week, repeat-dose toxicity study in cynomolgus monkeys. Weekly administration of atezolizumab to female monkeys at the highest dose tested caused an irregular menstrual cycle pattern and a lack of newly formed corpora lutea in the ovaries. This effect occurred at an estimated AUC approximately 6 times the AUC in patients receiving the recommended intravenous atezolizumab dose and was reversible. There was no effect on the male monkey reproductive organs.

Hyaluronidases are found in most tissues of the body. Long-term animal studies have not been performed to assess the carcinogenic or mutagenic potential of hyaluronidase. In addition, when up to 220,000 units/kg of subcutaneous hyaluronidase (recombinant human) was administered to cynomolgus monkeys for 39 weeks, which is > 223 times higher than the human recommended dose for hyaluronidase, no evidence of toxicity to the male or female reproductive system was found through periodic monitoring of in-life parameters (e.g., semen analyses, hormone levels, menstrual cycles, and also from gross pathology, histopathology and organ weight data).
BACKGROUND AND OBJECTIVES: This study identified a clinically significant subset of patients with glioma with tumor outside of contrast enhancement present at autopsy and subsequently developed a method for detecting nonenhancing tumor using radio-pathomic mapping. We tested the hypothesis that autopsy-based radio-pathomic tumor probability maps would be able to noninvasively identify areas of infiltrative tumor beyond traditional imaging signatures.
METHODS: A total of 159 tissue samples from 65 subjects were aligned to MRI acquired nearest to death for this retrospective study. Demographic and survival characteristics for patients with and without tumor beyond the contrast-enhancing margin were computed. An ensemble algorithm was used to predict pixelwise tumor presence from pathological annotations using segmented cellularity (Cell), extracellular fluid, and cytoplasm density as input (6 train/3 test subjects). A second level of ensemble algorithms was used to predict voxelwise Cell, extracellular fluid, and cytoplasm on the full data set (43 train/22 test subjects) using 5-by-5 voxel tiles from T1, T1 + C, fluid-attenuated inversion recovery, and apparent diffusion coefficient as input. The models were then combined to generate noninvasive whole brain maps of tumor probability.
RESULTS: Tumor outside of contrast was identified in 41.5% of patients, who showed worse survival outcomes (hazard ratio = 3.90, P < .001). Tumor probability maps reliably tracked nonenhancing tumor on a range of local and external unseen data, identifying tumor outside of contrast in 69% of presurgical cases that also showed reduced survival outcomes (hazard ratio = 1.67, P = .027).
CONCLUSION: This study developed a multistage model for mapping gliomas using autopsy tissue samples as ground truth, which was able to identify regions of tumor beyond traditional imaging signatures.
A wet wipe comprises a first nonwoven fibrous layer 102 made of continuous polyolefin filaments and produced by a first respective nonwoven manufacturing process; a second nonwoven fibrous layer 104 made of polyolefin filaments, said second nonwoven fibrous layer being produced by a second respective nonwoven manufacturing process; and a third nonwoven fibrous layer 106 made of continuous polyolefin filaments and produced by a third respective nonwoven manufacturing process. The second nonwoven fibrous layer 104 being located between said first nonwoven fibrous layer 102 and said third nonwoven fibrous layer 104. The first, second and third nonwoven fibrous layers 102, 104, 106 are bonded together to form a multilayered nonwoven fabric. Liquid is retained in the multilayered nonwoven fabric and said liquid wets said multilayered nonwoven fabric, the dry volume of said multilayered nonwoven fabric is substantially unchanged after retaining said liquid. The density of the dry said multilayered nonwoven fabric is at least 0.15 grams per centimetre cube. A method of manufacture is also disclosed.
The present invention relates to a method for preparing cosmetic base oil. Oil tea seeds are selected as the raw material of the cosmetic base oil; the oil tea seeds are softened and flaked after being cleaned, cooled, shelled and broken; obtained raw flakes are squeezed under normal temperature after being cooked to become cooked flakes. Obtained crude oil is filtered and separated in a centrifugal mode; colloid, such as phospholipid, etc. in the crude oil sucks water to expand, agglomerates and deposits to be separated from the oil by a low-temperature hydrolysis degumming method. The color of grease is improved by an adsorptive decoloring method of active white clay. Finally, the cosmetic base oil using tea oil as a base material is obtained. The present invention has the advantages of simple technology and wide source of raw materials, and reduces product cost. The prepared cosmetic base oil reserves many nutrient components beneficial to human bodies, and has natural anti-oxidation components of high content.
FIELD: chemical technology, chemical-pharmaceutical industry, pharmacy. SUBSTANCE: process is carried out by addition of sodium hydrosulfite to an aqueous-alkaline solution of 5-phenylazosalicylic acid at 20-40 C in a single stage, reductive reaction at 80-85 C, separation of aniline at the room temperature in the presence of nonionogenic surface-active substance, purification from residual impurities in the presence of nonionogenic surface-active substance at 60-70 C and pH 5.8-6.2, extraction with benzene and then with coal followed by isolation of the end product by acidification with acetic acid to pH 4.0-5.0. Neonols AF 9-10 and AF 9-12 are used as nonionogenic surface-active substances in the amount 0.4-0.8% of parent 5-phenylazosalicylic acid weight. The yield of 5-aminosalicylic acid is 84.7-86.1% as measures for 5-phenyl-azosalicylic acid. Method provides alternation of conditions of reduction of 5-phenylazosalicylic acid with sodium hydro-sulfite and separation of aniline and impurities from reactive solution after reduction reaction termination. EFFECT: simplified industrial method of synthesis, high yield of product. 2 cl, 1 tbl, 6 ex
The utility model relates to a face mask cloth which comprises a body with two eudipleural eyeholes and a mouth hole. The face mask cloth is characterized in that ear strips made to be integrative with the body are also included and are respectively arranged at the left side and the right side of the body, and hanging holes are formed between the ear strips and the body. Due to the adoption of the structure, the body which has a certain expansion and contraction is adhered to the face, and the two ear strips are respectively hung on the left ear and the right ear through the hanging holes so as to compact and compress the face and enhance the adhering capability. Due to the continuous compactness and compression of the body to the face, the continuous infiltration capacity of skin-protection liquid or emulsion is kept, and the absorption of the face to the skin-protection liquid or emulsion is improved. Moreover, because the body has a certain expansion and contraction capability, the bodies of the same model can suit people with different figures and face contours. Along with the stress relaxation of the face, the massage function to the face is formed, and the absorption capability to the skin-protection liquid or emulsion is further improved while the body is prevented from falling off.
Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
Ethylene Diamine Hydroxy Phenylacetic Acid (EDHPA) type chelators strongly bind paramagnetic metal ions to provide excellent contrast agents for magnetic resonance (MR) imaging. The magnetic dipole generated by unpaired electrons within the paramagnetic (PM) atom, causes a local reduction in the bulk magnetic field of the MR system. The resulting shortening of the T1 (spin lattice) relaxation time in the hydrogen protons within the area of interest, causes an intense "free induction signal" and a corresponding modulation in the collected scanning data. The tissue of organ of interest appears on the MR display as a high intensity of white area. Background tissue is displayed as darker or lower intensity greys. Each member chelator EDHPA' of the EDHPA family of chelators, is a phenolic analog of EDTA, with variations in the para position radical (PR) of the phenol ring. Each EDHPA' chelator is formed by twin amino acid molecules (phenylalanine etc), which provide twin chelation units having three coordination points each for binding the paramagnetic metal.
Approximately 50 subjects who are scheduled for multifocal IOL implantation and enrolled in the study will be randomized into the Symfony arm. Subjects will be implanted bilaterally with the CE marked TECNIS Symfony® IOL and assessed according to the study visit schedule.
Several genetic markers have shown associations with muscle performance and physical abilities, but the response to exercise therapy is still unknown. The aim of this study was to test the response of patients with long COVID through an aerobic physical therapy strategy by the Nordic walking program and how several genetic polymorphisms involved in muscle performance influence physical capabilities. Using a nonrandomized controlled pilot study, 29 patients who previously suffered from COVID-19 (long COVID = 13, COVID-19 = 16) performed a Nordic walking exercise therapy program for 12 sessions. The influence of the ACE (rs4646994), ACTN3 (rs1815739), AMPD1 (rs17602729), CKM (rs8111989), and MLCK (rs2849757 and rs2700352) polymorphisms, genotyped by using single nucleotide primer extension (SNPE) in lactic acid concentration was established with a three-way ANOVA (group × genotype × sessions). For ACE polymorphism, the main effect was lactic acid (p = 0.019). In ACTN3 polymorphism, there were no main effects of lactic acid, group, or genotype. However, the posthoc analysis revealed that, in comparison with nonlong COVID, long COVID increased lactic acid concentrations in Nordic walking sessions in CT and TT genotypes (all p < 0.05). For AMPD1 polymorphism, there were main effects of lactic acid, group, or genotype and lactic acid × genotype or lactic acid × group × genotype interactions (all p < 0.05). The posthoc analysis revealed that, in comparison with nonlong COVID, long COVID increased lactic acid concentrations in Nordic walking sessions in CC and CT genotypes (all p < 0.05). Physical therapy strategy through Nordic walking enhanced physical capabilities during aerobic exercise in post-COVID19 patients with different genotypes in ACTN3 c.1729C>T and AMPD1 c.34C>T polymorphisms. These findings suggest that individuals who reported long COVID who presumably exercised less beforehand appeared to be less able to exercise, based on lactate levels, and the effect of aerobic physical exercise enhanced physical capabilities conditioned by several genetic markers in long COVID patients.
Numerous of factors affect the immunological response during surgery. Despite intensive research, the impact of different anesthetic techniques on the immune system remains unclear.

Aim of this ex vivo / in vitro study was to determine the effects of general and neuraxial anesthesia on monocyte subset alteration and the release of prototypical pro- and anti-inflammatory cytokines. Twenty patients undergoing total knee replacement surgery were randomly assigned to receive either general anesthesia (ITN) or combined spinal/epidural anesthesia (CSE). Samples of venous blood were taken from the patients before and after induction of anesthesia, immediately, 6 hours, 24 hours, and 48 hours after surgery. All blood samples were incubated in presence or absence of LPS (lipopolysaccharide; 1 µg/ml) for 24 hours. CD14 and HLA-DR expression patterns on monocytes and intracellular TNF-alpha production were quantified via flow cytometry. TNF-α and IL-10 release were measured via enzyme linked immunosorbent assay (ELISA).
Compounds and methods for interrupting the interaction between Epstein-Barr virus encoded proteins known as LMP1 and Tumor Necrosis Factor Receptor Associated Factors (TRAFs), particularly novel human TRAFs, thereby inhibiting lymphoblast growth and tumorigenesis, particularly Hodgkin's disease, Burkitt's lymphoma, lymphomas seen in immunocompromised patients (including AIDS-associated central nervous system lymphomas), and nasopharyngeal carcinomas. Therapies for treating EBV infection are also disclosed, e.g. in patients with infectious mononucleosis, by blocking the establishment of latent infection and/or blocking lytic infection. Compounds and methods for controlling TRAF-Mediated TNF/TNFR signaling by administering to a TRAF-encoding cell a compound that inhibits TRAF oligomerization are also disclosed. Compounds and methods for controlling cell growth and death based on the interaction of TNF receptor family carboxy terminal cytoplasmic domains with human TRAFs, e.g., LAP1 and EBI6. These interactions are particularly important in controlling cells in the immune system and regulating immune responses. They are also important for controlling abnormally growing cells, that is cancer cells.
An immunogenic composition comprises a vector that cannot replicate in the respiratory tract of the host and a pharmaceutically acceptable carrier. The vector comprises a first nucleotide sequence encoding a RSV G protein, in which the transmembrane coding sequence and upstream sequence are absent, a promoter sequence operatively coupled to the first nucleotide sequence and a second nucleotide sequence located between the first nucleotide sequence and the promoter sequence. The composition generates protective antibodies to respiratory syncytial virus (RSV) G protein in the host. A vector, comprising a first nucleotide sequence encoding a RSV G protein and a promoter sequence operatively linked to the first nucleotide sequence, is used in the manufacture of a medicament that is suitable for immunizing against infection caused by RSV.  The vector may further comprise a heterologous signal peptide encoding nucleotide sequence, wherein the signal peptide preferably encodes human tissue plasminogen activator. The promoter is preferably an immediate early cytomegalovirus promoter.